Lite Strategy, Inc. (LITS)
NASDAQ: LITS · Real-Time Price · USD
1.930
+0.030 (1.58%)
At close: Nov 18, 2025, 4:00 PM EST
1.960
+0.030 (1.55%)
After-hours: Nov 18, 2025, 5:22 PM EST
Lite Strategy Market Cap
Lite Strategy has a market cap or net worth of $71 million as of November 18, 2025. Its market cap has increased by 242.97% in one year.
Market Cap
71.00M
Enterprise Value
61.99M
1-Year Change
242.97%
Ranking
Category
Stock Price
$1.93
Market Cap Chart
Since December 18, 2003, Lite Strategy's market cap has decreased from $424.10M to $71.00M, a decrease of -83.26%. That is a compound annual growth rate of -7.83%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 17, 2025 | 69.90M | 326.22% |
| Dec 31, 2024 | 16.40M | -57.51% |
| Dec 29, 2023 | 38.60M | 18.77% |
| Dec 30, 2022 | 32.50M | -89.20% |
| Dec 31, 2021 | 301.00M | 1.31% |
| Dec 31, 2020 | 297.10M | 62.62% |
| Dec 31, 2019 | 182.70M | -2.72% |
| Dec 31, 2018 | 187.80M | 141.70% |
| Dec 29, 2017 | 77.70M | 46.60% |
| Dec 30, 2016 | 53.00M | -2.93% |
| Dec 31, 2015 | 54.60M | -40.85% |
| Dec 31, 2014 | 92.30M | -46.40% |
| Dec 31, 2013 | 172.20M | 580.63% |
| Dec 31, 2012 | 25.30M | 105.69% |
| Dec 30, 2011 | 12.30M | 73.24% |
| Dec 31, 2010 | 7.10M | -86.19% |
| Dec 31, 2009 | 51.40M | - |
| Dec 31, 2008 | 51.40M | -74.17% |
| Dec 31, 2007 | 199.00M | 2.58% |
| Dec 29, 2006 | 194.00M | -45.49% |
| Dec 30, 2005 | 355.90M | -30.12% |
| Dec 31, 2004 | 509.30M | -23.48% |
| Dec 31, 2003 | 665.60M | 56.94% |
| Dec 18, 2003 | 424.10M | - |
View and export this data all the way back to 2003. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 918.02B |
| Johnson & Johnson | 472.05B |
| AbbVie | 410.67B |
| UnitedHealth Group | 291.55B |
| AstraZeneca | 276.16B |
| Novartis AG | 252.58B |
| Merck & Co. | 230.63B |
| Abbott Laboratories | 227.08B |